Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Humanistic burden and health-related quality of life

10 evidence topics · 11 sources

Radical cystectomy versus bladder-sparing therapy: 12-month patient-reported outcomes in recurrent high-grade NMIBC after BCG

“Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At 12 months, the primary outcome of EORTC QLQ-C30 physical function did not differ between the BST arm and the RC arm (mean 85.4 [SD, 17.7] v 86.2 [17.6], respectively; ATE, 0.9 [95% CI, –0.6 to 2.4]; P = .22; Fig 2, Data Supplement, Table S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Emotional function, cognitive function, global health, anxiety, and depression were significantly better in the RC arm 12 months after enrollment (Fig 2). There were no significant differences between treatment arms in role function and social function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants in the RC arm had significantly worse 12-month bowel and sexual summary scores than those in the BST arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“EORTC QLQ-C30 physical and role function were significantly worse in the RC arm at 3 months compared with the BST arm, but no significant treatment effects were observed by 9 months, including for physical function among participants age 75 years and older. Emotional function and anxiety were better in the RC arm at all follow-up time points. Urinary and bowel health were significantly worse in the RC arm at 3 months. By 12 months, there were no significant differences between the two treatments with respect to urinary health, but bowel health remained worse in the RC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Utility values used in a U.S. cost-effectiveness model of BCG-unresponsive carcinoma in situ
Health stateUtility valueRangeToll
Bladder cancer“0.95”View highlighted excerpt for this quote“0.93–0.97”View highlighted excerpt for this quote“Lifetime”View highlighted excerpt for this quote
Radical cystectomy with ileal conduit“0.8”View highlighted excerpt for this quote“0.7–0.9”View highlighted excerpt for this quote“3 months”View highlighted excerpt for this quote
Neoadjuvant chemotherapy, radical cystectomy, and ileal conduit“0.694”View highlighted excerpt for this quote“0.6–0.9”View highlighted excerpt for this quote“3 months”View highlighted excerpt for this quote
Post-cystectomy state“0.9”View highlighted excerpt for this quote“0.8–0.95”View highlighted excerpt for this quote“Lifetime”View highlighted excerpt for this quote
Metastatic disease“0.62”View highlighted excerpt for this quote“0.5–0.7”View highlighted excerpt for this quote“Lifetime”View highlighted excerpt for this quote
Recurrence“0.8”View highlighted excerpt for this quote“0.75–0.95”View highlighted excerpt for this quote“3 months”View highlighted excerpt for this quote
Disutility: acute minor toxicity (urinary tract infection)“−0.15”View highlighted excerpt for this quote“0–0.3”View highlighted excerpt for this quote“2 weeks”View highlighted excerpt for this quote
Disutility: acute major toxicity (hospitalization)“−0.2”View highlighted excerpt for this quote“0–0.3”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: recurrence (TURBT, restaging)“−0.15”View highlighted excerpt for this quote“0–0.3”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: radical cystectomy, major complications“−0.07”View highlighted excerpt for this quote“0–0.1”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: radical cystectomy, minor complications“−0.03”View highlighted excerpt for this quote“0–0.1”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: metastasis, initial“−0.28”View highlighted excerpt for this quote“0.1–0.4”View highlighted excerpt for this quote“1.5 month”View highlighted excerpt for this quote